BioNTech SE (22UA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, BioNTech SE (22UA) has a cash flow conversion efficiency ratio of -0.023x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-421.00 Million ≈ $-492.19 Million USD) by net assets (€18.70 Billion ≈ $21.86 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see 22UA stock market capitalisation for the company's overall valuation and market capitalisation.
BioNTech SE - Cash Flow Conversion Efficiency Trend (2017–2025)
This chart illustrates how BioNTech SE's cash flow conversion efficiency has evolved over time, based on yearly financial data.
BioNTech SE Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of BioNTech SE ranked by their cash flow conversion efficiency. Explore BioNTech SE cash flow quality index to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Canon Inc
F:CNNA
|
0.045x |
|
Bank of Shanghai Co Ltd
SHG:601229
|
-0.001x |
|
Super Micro Computer Inc
NASDAQ:SMCI
|
-0.873x |
|
CHINA SHENHUA EN.A ADR/4
F:IKFC
|
N/A |
|
Shanxi Xinghuacun Fen Wine Factory Co Ltd
SHG:600809
|
0.080x |
|
Reliance Steel & Aluminum Co
NYSE:RS
|
0.021x |
|
Henkel AG & Co. KGaA
XETRA:HEN
|
0.041x |
|
InterGlobe Aviation Limited
NSE:INDIGO
|
1.544x |
Annual Cash Flow Conversion Efficiency for BioNTech SE (2017–2025)
The table below shows the annual cash flow conversion efficiency of BioNTech SE from 2017 to 2025. View today's stock price for BioNTech SE for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €19.22 Billion ≈ $22.48 Billion |
€456.00 Million ≈ $533.11 Million |
0.024x | +121.68% |
| 2024-12-31 | €19.41 Billion ≈ $22.69 Billion |
€207.70 Million ≈ $242.82 Million |
0.011x | -95.97% |
| 2023-12-31 | €20.25 Billion ≈ $23.67 Billion |
€5.37 Billion ≈ $6.28 Billion |
0.265x | -60.81% |
| 2022-12-31 | €20.06 Billion ≈ $23.45 Billion |
€13.58 Billion ≈ $15.87 Billion |
0.677x | +805.01% |
| 2021-12-31 | €11.89 Billion ≈ $13.90 Billion |
€889.70 Million ≈ $1.04 Billion |
0.075x | +860.15% |
| 2020-12-31 | €1.37 Billion ≈ $1.60 Billion |
€-13.50 Million ≈ $-15.78 Million |
-0.010x | +97.55% |
| 2019-12-31 | €493.49 Million ≈ $576.94 Million |
€-198.50 Million ≈ $-232.07 Million |
-0.402x | -82.41% |
| 2018-12-31 | €267.00 Million ≈ $312.15 Million |
€-58.88 Million ≈ $-68.83 Million |
-0.221x | -120.22% |
| 2017-12-31 | €-48.21 Million ≈ $-56.36 Million |
€-52.56 Million ≈ $-61.45 Million |
1.090x | -- |
About BioNTech SE
BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus. It also develops oncology drugs under Phase III clinical trial, including Gotistobart for metastatic non-small cell lung cancer, Pumitamig for small cell lung cancer and advanced/metastatic tr… Read more